Détail d'une personne de l'annuaire - fr | Cancéropôle Est, la recherche innovante dans la lutte contre le cancer

Respective contribution of baseline clinical data, tumour metabolism and tumour blood-flow in predicting pCR after neoadjuvant chemotherapy in HER2 and Triple Negative breast cancer.

Payan N, Presles B, Coutant C, Desmoulins I, Ladoire S, Beltjens F, Brunotte F, Vrigneaud JM, Cochet A

EJNMMI Res. 2024 07 4;14(1):60

A Practical Quality Assurance Procedure for Data Acquisitions in Preclinical Simultaneous PET/MR Systems.

Courteau A, McGrath J, Walker PM, Presles B, Garipov R, Cochet A, Brunotte F, Vrigneaud JM

Mol Imaging Biol. 2022 12 7;:

Critical analysis of the effect of various methodologies to compute breast cancer tumour blood flow-based texture features using first-pass F-FDG PET.

Payan N, Presles B, Truntzer C, Courcet E, Coutant C, Desmoulins I, Brunotte F, Vrigneaud JM, Cochet A

Phys Med. 2022 10 16;103:98-107

[I]MIBG is a better early marker of anthracycline cardiotoxicity than [F]FDG: a preclinical SPECT/CT and simultaneous PET/MR study.

Oudot A, Courteau A, Guillemin M, Vrigneaud JM, Walker PM, Brunotte F, Cochet A, Collin B

EJNMMI Res. 2021 Sep 20;11(1):92

Performance evaluation and compatibility studies of a compact preclinical scanner for simultaneous PET/MR imaging at 7 Tesla.

Courteau A, McGrath J, Walker PM, Pegg R, Martin G, Garipov R, Doughty P, Cochet A, Brunotte FC, Vrigneaud JM

IEEE Trans Med Imaging. 2020 Sep 21;PP:

Biological correlates of tumor perfusion and its heterogeneity in newly diagnosed breast cancer using dynamic first-pass F-FDG PET/CT.

Payan N, Presles B, Brunotte F, Coutant C, Desmoulins I, Vrigneaud JM, Cochet A

Eur. J. Nucl. Med. Mol. Imaging. 2019 Aug 8;:

Combination of breast imaging parameters obtained from F-FDG PET and CT scan can improve the prediction of breast-conserving surgery after neoadjuvant chemotherapy in luminal/HER2-negative breast cancer.

Grapin M, Coutant C, Riedinger JM, Ladoire S, Brunotte F, Cochet A, Humbert O

Eur J Radiol. 2019 Apr;113:81-88

Innovative Magnetic Nanoparticles for PET/MRI Bimodal Imaging.

Thomas G, Boudon J, Maurizi L, Moreau M, Walker P, Severin I, Oudot A, Goze C, Poty S, Vrigneaud JM, Demoisson F, Denat F, Brunotte F, Millot N

ACS Omega. 2019 Feb 28;4(2):2637-2648

Automatic classification of tissues on pelvic MRI based on relaxation times and support vector machine.

Zavala Bojorquez JA, Jodoin PM, Bricq S, Walker PM, Brunotte F, Lalande A

PLoS ONE. 2019 ;14(2):e0211944

Radiolabeled F(ab')-cetuximab for theranostic purposes in colorectal and skin tumor-bearing mice models.

Bellaye PS, Moreau M, Raguin O, Oudot A, Bernhard C, Vrigneaud JM, Dumont L, Vandroux D, Denat F, Cochet A, Brunotte F, Collin B

Clin Transl Oncol. 2018 May 17;:

Initial performance evaluation of a preclinical PET scanner available as a clip-on assembly in a sequential PET/MRI system.

Vrigneaud JM, McGrath J, Courteau A, Pegg R, Sanchez-Pastor Gomis A, Camacho A, Martin G, Schramm N, Brunotte F

Phys Med Biol. 2018 May 15;:

Pattern of breast cancer blood flow and metabolism, assessed using dual-acquisition FDG PET: correlation with tumor phenotypic features and pathological response to neoadjuvant chemotherapy.

Humbert O, Lasserre M, Bertaut A, Fumoleau P, Coutant C, Brunotte F, Cochet A

J. Nucl. Med.. 2018 Feb 9;:

Automatic deformable PET/MRI registration for preclinical studies based on B-splines and non-linear intensity transformation.

Bricq S, Kidane HL, Zavala-Bojorquez J, Oudot A, Vrigneaud JM, Brunotte F, Walker PM, Cochet A, Lalande A

Med Biol Eng Comput. 2018 Feb 7;:

SUV calculation in breast cancer: which normalization should be applied when using 18F-FDG PET?

Humbert O, Riedinger JM, Chardin D, Desmoulins I, Brunotte F, Cochet A

Q J Nucl Med Mol Imaging. 2018 Jan 17;:

FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCIST.

Depardon E, Kanoun S, Humbert O, Bertaut A, Riedinger JM, Tal I, Vrigneaud JM, Lasserre M, Toubeau M, Berriolo-Riedinger A, Dygai-Cochet I, Fumoleau P, Brunotte F, Cochet A

PLoS ONE. 2018 ;13(7):e0199529

Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model.

Bellaye PS, Oudot A, Vrigneaud JM, Raguin O, Bichat F, Vaslin A, Maby-El Hajjami H, Zanna C, Vuagniaux G, Fumoleau P, Denat F, Brunotte F, Collin B

Contrast Media Mol Imaging. 2018 ;2018:8494031

MANOTA: a promising bifunctional chelating agent for copper-64 immunoPET.

Moreau M, Poty S, Vrigneaud JM, Walker P, Guillemin M, Raguin O, Oudot A, Bernhard C, Goze C, Boschetti F, Collin B, Brunotte F, Denat F

Dalton Trans. 2017 Sep;:

(18)F-Choline Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging for the Detection of Early Local Recurrence of Prostate Cancer Initially Treated by Radiation Therapy: Comparison With Systematic 3-Dimensional T

Kanoun S, Walker P, Vrigneaud JM, Depardon E, Barbier V, Humbert O, Moulin M, Créhange G, Cormier L, Loffroy R, Brunotte F, Cochet A

Int. J. Radiat. Oncol. Biol. Phys.. 2017 Apr;97(5):986-994

What are normal relaxation times of tissues at 3 T?

Bojorquez JZ, Bricq S, Acquitter C, Brunotte F, Walker PM, Lalande A

Magn Reson Imaging. 2017 Jan;35:69-80

18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast Cancer.

Humbert O, Riedinger JM, Vrigneaud JM, Kanoun S, Dygai-Cochet I, Berriolo-Riedinger A, Toubeau M, Depardon E, Lassere M, Tisserand S, Fumoleau P, Brunotte F, Cochet A

J. Nucl. Med.. 2016 Nov;57(11):1707-1712

A novel alternative to classify tissues from T 1 and T 2 relaxation times for prostate MRI.

Bojorquez JZ, Bricq S, Brunotte F, Walker PM, Lalande A

MAGMA. 2016 Oct;29(5):777-88

Near-Infrared-Emitting BODIPY-trisDOTA(111) In as a Monomolecular Multifunctional Imaging Probe: From Synthesis to In Vivo Investigations.

Maindron N, Ipuy M, Bernhard C, Lhenry D, Moreau M, Carme S, Oudot A, Collin B, Vrigneaud JM, Provent P, Brunotte F, Denat F, Goze C

Chemistry. 2016 Aug;22(36):12670-4

Minor changes in the macrocyclic ligands but major consequences on the efficiency of gold nanoparticles designed for radiosensitization.

Laurent G, Bernhard C, Dufort S, Jiménez Sánchez G, Bazzi R, Boschetti F, Moreau M, Vu TH, Collin B, Oudot A, Herath N, Requardt H, Laurent S, Vander Elst L, Muller R, Dutreix M, Meyer M, Brunotte F, Perriat P, Lux F, Tillement O, Le Duc G, Denat F, Roux S

Nanoscale. 2016 Jun;8(23):12054-65

BODIPY: A Highly Versatile Platform for the Design of Bimodal Imaging Probes.

Lhenry D, Larrouy M, Bernhard C, Goncalves V, Raguin O, Provent P, Moreau M, Collin B, Oudot A, Vrigneaud JM, Brunotte F, Goze C, Denat F

Chemistry. 2015 Sep 7;21(37):13091-9

Identification of biomarkers including 18FDG-PET/CT for early prediction of response to neoadjuvant chemotherapy in Triple Negative Breast Cancer.

Humbert O, Riedinger JM, Charon-Barra C, Berriolo-Riedinger A, Desmoulins I, Lorgis V, Kanoun S, Coutant C, Fumoleau P, Cochet A, Brunotte F

Clin Cancer Res. 2015 Jun 30. pii: clincanres.0384.2015.

ProstateAnalyzer: web-based medical application for the management of prostate cancer using multiparametric MR imaging.

Mata C, Walker PM, Oliver A, Brunotte F, Marti J, Lalande A

Inform Health Soc Care. 2015 Feb 24:1-21.

Role of positron emission tomography for the monitoring of response to therapy in breast cancer.

Humbert O, Cochet A, Coudert B, Berriolo-Riedinger A, Kanoun S, Brunotte F, Fumoleau P

Oncologist. 2015 Feb;20(2):94-104

Influence of Software Tool and Methodological Aspects of Total Metabolic Tumor Volume Calculation on Baseline [18F]FDG PET to Predict Survival in Hodgkin Lymphoma.

Kanoun S, Tal I, Berriolo-Riedinger A, Rossi C, Riedinger JM, Vrigneaud JM, Legrand L, Humbert O, Casasnovas O, Brunotte F, Cochet A

PLoS One. 2015 Oct 16;10(10):e0140830

[Multimodality MRI and PET for restaging prostate cancer after biochemical failure of the treatment].

Cochet A, Kanoun S, Humbert O, Walker PM, Cormier L, Crehange G, Brunotte F

Cancer Radiother. 2014 Oct;18(5-6):509-16

Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma.

Kanoun S, Rossi C, Berriolo-Riedinger A, Dygai-Cochet I, Cochet A, Humbert O, Toubeau M, Ferrant E, Brunotte F, Casasnovas RO

Eur J Nucl Med Mol Imaging. 2014 Sep;41(9):1735-43

HER2-positive breast cancer: (1)(8)F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.

Humbert O, Cochet A, Riedinger JM, Berriolo-Riedinger A, Arnould L, Coudert B, Desmoulins I, Toubeau M, Dygai-Cochet I, Guiu S, Coutant C, Fumoleau P, Brunotte F

Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1525-33

Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.

Rossi C, Kanoun S, Berriolo-Riedinger A, Dygai-Cochet I, Humbert O, Legouge C, Chretien ML, Bastie JN, Brunotte F, Casasnovas RO

J Nucl Med. 2014 Apr;55(4):569-73

Pattern of occult nodal relapse diagnosed with (18)F-fluoro-choline PET/CT in prostate cancer patients with biochemical failure after prostate-only radiotherapy.

Lepinoy A, Cochet A, Cueff A, Cormier L, Martin E, Maingon P, Bosset JF, Brunotte F, Crehange G

Radiother Oncol. 2014 Apr;111(1):120-5

(1)(8)F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.

Cochet A, Dygai-Cochet I, Riedinger JM, Humbert O, Berriolo-Riedinger A, Toubeau M, Guiu S, Coutant C, Coudert B, Fumoleau P, Brunotte F

Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):428-37

Dual labeling of lipopolysaccharides for SPECT-CT imaging and fluorescence microscopy.

Duheron V, Moreau M, Collin B, Sali W, Bernhard C, Goze C, Gautier T, Pais de Barros JP, Deckert V, Brunotte F, Lagrost L, Denat F

ACS Chem Biol. 2014 Mar 21;9(3):656-62

Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer.

Humbert O, Berriolo-Riedinger A, Cochet A, Gauthier M, Charon-Barra C, Guiu S, Desmoulins I, Toubeau M, Dygai-Cochet I, Coutant C, Fumoleau P, Brunotte F

Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):416-27

Relationship between fragmented QRS and no-reflow, infarct size, and peri-infarct zone assessed using cardiac magnetic resonance in patients with myocardial infarction.

Lorgis L, Cochet A, Chevallier O, Angue M, Gudjoncik A, Lalande A, Zeller M, Buffet P, Brunotte F, Cottin Y

Can J Cardiol. 2014 Feb;30(2):204-10

Application of the optically stimulated luminescence (OSL) technique for mouse dosimetry in micro-CT imaging.

Vrigneaud JM, Courteau A, Ranouil J, Morgand L, Raguin O, Walker P, Oudot A, Collin B, Brunotte F

Med Phys. 2013 Dec;40(12):122102

In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.

Berthet L, Cochet A, Kanoun S, Berriolo-Riedinger A, Humbert O, Toubeau M, Dygai-Cochet I, Legouge C, Casasnovas O, Brunotte F

J Nucl Med. 2013 Aug;54(8):1244-50

Predictors of post-stress LVEF drop 6 months after reperfused myocardial infarction: a gated myocardial perfusion SPECT study.

Guenancia C, Cochet A, Humbert O, Dygai-Cochet I, Lorgis L, Zeller M, Stamboul K, Brunotte F, Cottin Y

Ann Nucl Med. 2013 Feb;27(2):112-22

Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes.

Humbert O, Berriolo-Riedinger A, Riedinger JM, Coudert B, Arnould L, Cochet A, Loustalot C, Fumoleau P, Brunotte F

Ann Oncol. 2012 Oct;23(10):2572-7

An adapted optical flow algorithm for robust quantification of cardiac wall motion from standard cine-MR examinations.

Xavier M, Lalande A, Walker PM, Brunotte F, Legrand L

IEEE Trans Inf Technol Biomed. 2012 Sep;16(5):859-68

DOTAGA-anhydride: a valuable building block for the preparation of DOTA-like chelating agents.

Bernhard C, Moreau M, Lhenry D, Goze C, Boschetti F, Rousselin Y, Brunotte F, Denat F

Chemistry. 2012 Jun 18;18(25):7834-41

DOTAGA-trastuzumab. A new antibody conjugate targeting HER2/Neu antigen for diagnostic purposes.

Moreau M, Raguin O, Vrigneaud JM, Collin B, Bernhard C, Tizon X, Boschetti F, Duchamp O, Brunotte F, Denat F

Bioconjug Chem. 2012 Jun 20;23(6):1181-8

Evaluation of breast tumor blood flow with dynamic first-pass 18F-FDG PET/CT: comparison with angiogenesis markers and prognostic factors.

Cochet A, Pigeonnat S, Khoury B, Vrigneaud JM, Touzery C, Berriolo-Riedinger A, Dygai-Cochet I, Toubeau M, Humbert O, Coudert B, Fumoleau P, Arnould L, Brunotte F

J Nucl Med. 2012 Apr;53(4):512-20

MR spectroscopy compared with DW-MRI and DCE-MRI at 3-tesla for the noninvasive prediction of short-term radiation response for patients with localized prostate cancer.

Crehange G, Maingon P, Gauthier M, Cochet A, Martin E, Mirjolet-Didelot C, Cormier L, Bonnetain F, Vignon N, Brunotte F, Walker PM

J. Clin. Oncol.. 2012 Feb;30(5_suppl):122

Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer.

Cochet A, Quilichini G, Dygai-Cochet I, Touzery C, Toubeau M, Berriolo-Riedinger A, Coudert B, Cottin Y, Fumoleau P, Brunotte F

Breast Cancer Res Treat. 2011 Dec;130(3):845-54

Early choline levels from 3-tesla MR spectroscopy after exclusive radiation therapy in patients with clinically localized prostate cancer are predictive of plasmatic levels of PSA at 1 year.

Crehange G, Maingon P, Gauthier M, Parfait S, Cochet A, Mirjolet C, Bonnetain F, Cormier L, Brunotte F, Walker P

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e407-13

Tumor volume and metabolism of prostate cancer determined by proton magnetic resonance spectroscopic imaging at 3T without endorectal coil reveal potential clinical implications in the context of radiation oncology.

Crehange G, Parfait S, Liegard M, Maingon P, Ben Salem D, Cochet A, Funes de la Vega M, Cormier L, Bonnetain F, Mirjolet C, Brunotte F, Walker PM

Int J Radiat Oncol Biol Phys. 2011 Jul 15;80(4):1087-94

Prognostic value of initial F-18-FDG-PET in patients with oesophageal carcinoma treated by exclusive radiochemotherapy.

Humbert O, Dygai-Cochet I, Gauthier M, Cochet A, Berriolo-Riedinger A, Crehange G, Toubeau M, Brunotte F

. 2011 Apr;35(4):186-94.

Biphasic time course of brain water ADC observed during the first month of life in term neonates with severe perinatal asphyxia is indicative of poor outcome at 3 years.

Boichot C, Mejean N, Gouyon JB, Brunotte F, Walker PM

Magn Reson Imaging. 2011 Feb;29(2):194-201

Prognostic value of microvascular damage determined by cardiac magnetic resonance in non ST-segment elevation myocardial infarction: comparison between first-pass and late gadolinium-enhanced images.

Cochet A, Lalande A, Lorgis L, Zeller M, Beer JC, Walker PM, Touzery C, Wolf JE, Cottin Y, Brunotte F

Invest Radiol. 2010 Nov;45(11):725-32.

Clinical experience with a novel thermosensitive temporary coronary artery occluder (LeGoo).

Bouchot O, Berger RL, Berne JP, Brunotte F, Brenot R

Ann Thorac Surg. 2010 Jun;89(6):1912-7.

Congenital complete absence of the left pericardium: a rare cause of chest pain or pseudo-right heart overload.

Garnier F, Eicher JC, Philip JL, Lalande A, Bieber H, Voute MF, Brenot R, Brunotte F, Wolf JE

Clin Cardiol. 2010 Feb;33(2):E52-7.

Influence of age and sex on aortic distensibility assessed by MRI in healthy subjects.

Rose JL, Lalande A, Bouchot O, Bourennane el-B, Walker PM, Ugolini P, Revol-Muller C, Cartier R, Brunotte F

Magn Reson Imaging. 2010 Feb;28(2):255-63

Place of imaging in the evaluation of treatment response in breast cancer

Brunotte F, Berriolo-Riedinger A, Cochet A, Toubeau M, Dygai-Cochet I, Riedinger JM

Med Nucl-imag Fonct Metab. 2010 Jan;34(1):58-65

[Magnetic resonance spectroscopy: a new standard for quantification of liver steatosis?]

Guiu B, Petit JM, Walker PM, Loffroy R, Hillon P, Brunotte F, Krause D, Cercueil JP

Gastroenterol Clin Biol. 2009 Oct-Nov;33(10-11):967-70

Major prognostic impact of persistent microvascular obstruction as assessed by contrast-enhanced cardiac magnetic resonance in reperfused acute myocardial infarction.

Cochet AA, Lorgis L, Lalande A, Zeller M, Beer JC, Walker PM, Touzery C, Wolf JE, Brunotte F, Cottin Y

Eur Radiol. 2009 Sep;19(9):2117-26

Pseudoplanar images obtained from pulmonary SPECT: Agreement of reading and comparison to planar images

Clappuccini R, Boichot C, Cochet A, Touzery C, Dygai-Cochet I, Berriolo-Riedinger A, Toubeau M, Brunotte F

Med Nucl-imag Fonct Metab. 2009 Apr;33(4):169-80

Bone metastasis of a breast cancer detected by 3 '-deoxy-3 '-F-18-fluorothymidine PET/CT

Cochet A, Berriolo-Riedinger A, Girault S, Rousseau C, Brunotte F, Couturier O

Nuklearmedizin. 2009;48(5):N45-6.

Brain flexibility and balance and gait performances mark morphological and metabolic abnormalities in the elderly.

Ben Salem D, Walker PM, Aho S, Tavernier B, Giroud M, Tzourio C, Ricolfi F, Brunotte F

J Clin Neurosci. 2008 Dec;15(12):1360-5

Compliance and pulse wave velocity assessed by MRI detect early aortic impairment in young patients with mutation of the smooth muscle myosin heavy chain.

Lalande A, Khau Van Kien P, Walker PM, Zhu L, Legrand L, Claustres M, Jeunemaitre X, Brunotte F, Wolf JE

J Magn Reson Imaging. 2008 Nov;28(5):1180-7.

N-acetylaspartate/creatine and choline/creatine ratios in the thalami, insular cortex and white matter as markers of hypertension and cognitive impairment in the elderly.

Ben Salem D, Walker PM, Bejot Y, Aho SL, Tavernier B, Rouaud O, Ricolfi F, Brunotte F

Hypertens Res. 2008 Oct;31(10):1851-7.

A deformable model-based system for 3D analysis and visualization of tumor in PET/CT images.

Landre J, Lebonvallet S, Ruan S, Xiaobing L, Tianshuang Q, Brunotte F

Conf Proc IEEE Eng Med Biol Soc. 2008;2008:3130-3.

Utility of Cardiac Magnetic Resonance to assess association between admission hyperglycemia and myocardial damage in patients with reperfused ST-segment elevation myocardial infarction.

Cochet A, Zeller M, Lalande A, L'huillier I, Walker PM, Touzery C, Verges B, Wolf JE, Brunotte F, Cottin Y

J Cardiovasc Magn Reson. 2008 Jan 15;10(1):2.

[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy.

Berriolo-Riedinger A, Touzery C, Riedinger JM, Toubeau M, Coudert B, Arnould L, Boichot C, Cochet A, Fumoleau P, Brunotte F

Eur J Nucl Med Mol Imaging. 2007 Dec;34(12):1915-24

Comparison of the extent of delayed-enhancement cardiac magnetic resonance imaging with and without phase-sensitive reconstruction at 3.0 T.

Cochet A, Lalande A, Walker PM, Boichot C, Ciappuccini R, Cottin Y, Wolf JE, Brunotte F

Invest Radiol. 2007 Jun;42(6):372-6.

Term neonate prognoses after perinatal asphyxia: contributions of MR imaging, MR spectroscopy, relaxation times, and apparent diffusion coefficients.

Boichot C, Walker PM, Durand C, Grimaldi M, Chapuis S, Gouyon JB, Brunotte F

Radiology. 2006 Jun;239(3):839-48

Is NAA reduction in normal contralateral cerebral tissue in stroke patients dependent on underlying risk factors?

Walker PM, Ben Salem D, Giroud M, Brunotte F

J Neurol Neurosurg Psychiatry. 2006 May;77(5):596-600.

Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus.

Zhu L, Vranckx R, Khau Van Kien P, Lalande A, Boisset N, Mathieu F, Wegman M, Glancy L, Gasc JM, Brunotte F, Bruneval P, Wolf JE, Michel JB, Jeunemaitre X

Nat Genet. 2006 Mar;38(3):343-9